Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (422)	11/6/2003 1:37:40 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SGP Continues on the doldrums.<g> It seems it may retest its August 22 L of 14.16 in spite of all the changes that its CEO Fred Hassan has been making on his team since he took over last April.<g> forbes.com The stock has previously closed its August 22 downgap and needs to trade above its September 18 H of 16.82 in order to improve its chart pattern.<g> siliconinvestor.com The estimated earnings for the current year remain at $0.38/share and $0.35/share for 2004, but IMHO it may be good to keep SGP in mind for a possible buy after the tax selling season is over.(The cash flow remains around $1.68/share) bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (422)	12/18/2003 1:29:42 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

LSBC Has been up 74.4% today,albeit it is up only 48% at present.<g> It announced today its plans to commercialize a "revolutionary new diagnostic product called BAMF that enables breakthrough detection of cancer and other diseases through non-invasive, serum-based tests." BAMF is a proprietary pattern recognition discovery platform that detects key biomarkers to identify life-threatening diseases such as cancer. "BAMF successfully diagnosed 100% of the ovarian cancer patients vs. normal, using statistically relevant mass spectrometry data sets publicly available from a NCI/FDA study." All proteomics analysis will be headquartered in Vacaville since Eclipse Diagnostics, (LSBC's subsidiary)will be the one to commercialize BAMF based procedures. biz.yahoo.com LSBC stock traded today above its resistance at the 2.25 level but has failed to reach its Nov.13 H of 2.90 That H was made on a volume of 521,824. I think is better to wait and see if the stock will be able to close above that level, since on Nov.14 the stock tanked to 1.25 on a volume of 2,597,956 (Of course that was the day when LSBC announced that it would re-evaluate its fee-for-service proteomic contract research.<g>) On Nov.14 LSBC's President said: "As announced in April 2003, a re-evaluation of our 2Dimensional gel fee-for-service proteomic research business with the potential for attendant cost reduction is entirely consistent with our previously articulated strategic shift from platform technologies and contract proteomic research in favor of developing and commercializing vaccines and protein-based pharmaceutical products." (That was a pretty long paragraph, somewhat reminiscent of Alan Greenspan's estile .<g>) The conclusion of the toxicoproteomic contract with the NIEHS on Dec.15 also brought memories of the cancellation of contracts with DOW and others.<g> It also made people wonder about LSBC's financial future and worry about warnings on its 10Q <g>. A couple of days later,its president K.Ryan made this 4 statements: 1. Existing cash will cover six months' operation in 2004 at the current rate of cash utilization. 2. New government research contracts will provide an additional two months. 3. Sales of research-grade aprotinin for research and biomanufacturing applications by mid-2004. 4. Expected revenue deals and licenses are anticipated to cover the remaining months, for a full year's operation. The license agreement with the Cincinnati Children's Hospital Medical Center for the development of a drug to treat atherosclerosis,nnounced on Dec.18 helped to bring the stock price to the $2 level for a while.<g> It will be nice if LSBC stock can manage to close above the 2.25 level today.<g> bigcharts.marketwatch.com stockcharts.com stockcharts.com[m,a]waclyyay[pb50!b200][vc60][iUb14!La12,26,9]&pref=G Bernard